Cumberland Pharmaceuticals annual operating margin
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cumberland Pharmaceuticals's operating margin was −6.27% for fiscal 2025.
View full Cumberland Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −6.27% | +10.72 pp |
| 2024 | 2024-12-31 | −16.99% | +7.17 pp |
| 2023 | 2023-12-31 | −24.16% | −10.58 pp |
| 2022 | 2022-12-31 | −13.58% | +8.33 pp |
| 2021 | 2021-12-31 | −21.91% | −4.10 pp |
| 2020 | 2020-12-31 | −17.81% | +10.85 pp |
| 2019 | 2019-12-31 | −28.66% | +10.13 pp |
| 2018 | 2018-12-31 | −38.79% | −28.68 pp |
| 2017 | 2017-12-31 | −10.11% | −5.70 pp |
| 2016 | 2016-12-31 | −4.41% | −127.92 pp |
| 2015 | 2015-12-31 | 123.51% | −469.63 pp |
| 2014 | 2014-12-31 | 593.14% | +1068.31 pp |
| 2013 | 2013-12-31 | −475.17% | −1734.90 pp |
| 2012 | 2012-12-31 | 1,259.73% | +1240.47 pp |
| 2011 | 2011-12-31 | 19.26% | +5.09 pp |
| 2010 | 2010-12-31 | 14.17% | +0.90 pp |
| 2009 | 2009-12-31 | 13.27% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −35.91% | −7.12 pp |
| Q1 2026 | 2026-03-31 | −34.27% | −45.30 pp |
| Q4 2025 | 2025-12-31 | 7.32% | +24.97 pp |
| Q3 2025 | 2025-09-30 | −23.70% | −5.05 pp |
| Q2 2025 | 2025-06-30 | −28.78% | −18.36 pp |
| Q1 2025 | 2025-03-31 | 11.03% | +33.03 pp |
| Q4 2024 | 2024-12-31 | −17.65% | +48.41 pp |
| Q3 2024 | 2024-09-30 | −18.65% | −0.14 pp |
| Q2 2024 | 2024-06-30 | −10.42% | −10.63 pp |
| Q1 2024 | 2024-03-31 | −22.00% | −5.39 pp |
| Q4 2023 | 2023-12-31 | −66.07% | −41.10 pp |
| Q3 2023 | 2023-09-30 | −18.51% | −15.98 pp |
| Q2 2023 | 2023-06-30 | 0.21% | +18.14 pp |
| Q1 2023 | 2023-03-31 | −16.60% | −5.04 pp |
| Q4 2022 | 2022-12-31 | −24.97% | +34.03 pp |
| Q3 2022 | 2022-09-30 | −2.53% | +16.84 pp |
| Q2 2022 | 2022-06-30 | −17.93% | −2.07 pp |
| Q1 2022 | 2022-03-31 | −11.56% | −8.48 pp |
| Q4 2021 | 2021-12-31 | −59.00% | −38.84 pp |
| Q3 2021 | 2021-09-30 | −19.37% | −6.30 pp |
| Q2 2021 | 2021-06-30 | −15.85% | +0.62 pp |
| Q1 2021 | 2021-03-31 | −3.08% | +19.08 pp |
| Q4 2020 | 2020-12-31 | −20.16% | +26.18 pp |
| Q3 2020 | 2020-09-30 | −13.07% | +33.02 pp |
| Q2 2020 | 2020-06-30 | −16.47% | −1.89 pp |
| Q1 2020 | 2020-03-31 | −22.16% | −6.99 pp |
| Q4 2019 | 2019-12-31 | −46.34% | +341.13 pp |
| Q3 2019 | 2019-09-30 | −46.09% | −24.81 pp |
| Q2 2019 | 2019-06-30 | −14.58% | −6.03 pp |
| Q1 2019 | 2019-03-31 | −15.17% | +13.39 pp |
| Q4 2018 | 2018-12-31 | −387.47% | −379.16 pp |
| Q3 2018 | 2018-09-30 | −21.28% | −13.78 pp |
| Q2 2018 | 2018-06-30 | −8.55% | +10.84 pp |
| Q1 2018 | 2018-03-31 | −28.56% | −21.73 pp |
| Q4 2017 | 2017-12-31 | −8.31% | +2.91 pp |
| Q3 2017 | 2017-09-30 | −7.50% | −8.98 pp |
| Q2 2017 | 2017-06-30 | −19.39% | −17.97 pp |
| Q1 2017 | 2017-03-31 | −6.83% | −0.36 pp |
| Q4 2016 | 2016-12-31 | −11.22% | −14.65 pp |
| Q3 2016 | 2016-09-30 | 1.48% | −6.08 pp |
| Q2 2016 | 2016-06-30 | −1.42% | −1.47 pp |
| Q1 2016 | 2016-03-31 | −6.47% | −16.64 pp |
| Q3 2015 | 2015-09-30 | 3.44% | −9.03 pp |
| Q2 2015 | 2015-06-30 | 7.56% | +2.52 pp |
| Q1 2015 | 2015-03-31 | 0.05% | +23.25 pp |
| Q3 2014 | 2014-09-30 | 10.17% | +26.27 pp |
| Q2 2014 | 2014-06-30 | 12.47% | −0.46 pp |
| Q1 2014 | 2014-03-31 | 5.04% | −18.73 pp |
| Q3 2013 | 2013-09-30 | −23.20% | −38.89 pp |
| Q2 2013 | 2013-06-30 | −16.11% | −22.41 pp |
| Q1 2013 | 2013-03-31 | 12.93% | −0.20 pp |
| Q3 2012 | 2012-09-30 | 23.77% | +0.04 pp |
| Q2 2012 | 2012-06-30 | 15.69% | −9.55 pp |
| Q1 2012 | 2012-03-31 | 6.30% | −6.90 pp |
| Q4 2011 | 2011-12-31 | 13.13% | −6.92 pp |
| Q3 2011 | 2011-09-30 | 23.73% | +14.33 pp |
| Q2 2011 | 2011-06-30 | 25.24% | — |
| Q1 2011 | 2011-03-31 | 13.20% | — |
| Q3 2010 | 2010-09-30 | 20.05% | — |
| Q2 2010 | 2010-06-30 | 9.40% | — |
Over the last five reported fiscal years, Cumberland Pharmaceuticals's operating margin increased from −17.81% to −6.27%, a change of +11.53 percentage points. The latest reported quarter, Q2 2026, shows −35.91%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cumberland Pharmaceuticals filings at SEC.gov ↗